Back to Search Start Over

The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy

Authors :
Lionel A. Tintignac
Serge A. Leibovitch
Carlos T Segura
Nicolas Offner
Marie Pierre Leibovitch
Sabrina Batonnet-Pichon
Julie Lagirand-Cantaloube
Alfredo Csibi
Différenciation Cellulaire et Croissance (DCC)
Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)
Institut Cochin (UMR_S567 / UMR 8104)
Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Stress et pathologies du cytosquelette EA 300
Université Paris Diderot - Paris 7 (UPD7)
Source :
EMBO Journal, EMBO Journal, EMBO Press, 2008, 27 (8), pp.1266-1276
Publication Year :
2008
Publisher :
Wiley, 2008.

Abstract

International audience; In response to cancer, AIDS, sepsis and other systemic diseases inducing muscle atrophy, the E3 ubiquitin ligase Atrogin1/MAFbx (MAFbx) is dramatically upregulated and this response is necessary for rapid atrophy. However, the precise function of MAFbx in muscle wasting has been questioned. Here, we present evidence that during muscle atrophy MAFbx targets the eukaryotic initiation factor 3 subunit 5 (eIF3-f) for ubiquitination and degradation by the proteasome. Ectopic expression of MAFbx in myotubes induces atrophy and degradation of eIF3-f. Conversely, blockade of MAFbx expression by small hairpin RNA interference prevents eIF3-f degradation in myotubes undergoing atrophy. Furthermore, genetic activation of eIF3-f is sufficient to cause hypertrophy and to block atrophy in myotubes, whereas genetic blockade of eIF3-f expression induces atrophy in myotubes. Finally, eIF3-f induces increasing expression of muscle structural proteins and hypertrophy in both myotubes and mouse skeletal muscle. We conclude that eIF3-f is a key target that accounts for MAFbx function during muscle atrophy and has a major role in skeletal muscle hypertrophy. Thus, eIF3-f seems to be an attractive therapeutic target

Details

ISSN :
14602075 and 02614189
Volume :
27
Database :
OpenAIRE
Journal :
The EMBO Journal
Accession number :
edsair.doi.dedup.....53c16068a31a3a5b0bca55707d27c050
Full Text :
https://doi.org/10.1038/emboj.2008.52